uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 4 5 4

+8 more TTM periods

ROE
(157.61%) (228.24%) (207.10%) (165.27%)
ROA
(32.13%) (30.18%) (28.81%) (30.65%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(33.09%) (36.74%) (32.79%) (37.27%)
Average Days of Receivables
112.95 71.86 132.94 89.98
Free Cash Flow per Share
(2.44) (2.75) (3.10) (2.62)
Free Cash Flow
(161.45) (172.56) (178.40) (153.60)
Other line items

Show all line items

Columns are period end dates